Tumor necrosis factor inhibitors (TNFi) have significantly improved treatment outcome of
rheumatic diseases since their incorporation into treatment protocols two decades ago …

Background Data are scarce on immunogenicity of COVID-19 vaccines in patients with
autoimmune diseases, who are often treated with immunosuppressive drugs. We aimed to …

June 18, 2021 https://doi. org/10.1016/S2665-9913 (21) 00181-8 digital platforms has had
an adverse impact on diversity and participation from under-represented groups due to …

The socioeconomic burden of COVID-19 and pressure on health-care systems can only be
reduced by achieving herd immunity against SARS-CoV-2. For herd immunity to be …

Background Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough
infections in vaccinated patients with immune-mediated inflammatory diseases treated with …

There is a continuous debate about the risks of increased incidence of COVID-19 in
vulnerable patient groups, which includes patients with rheumatic diseases and especially …

Objective To develop EULAR points-to-consider for therapeutic drug monitoring (TDM) of
biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases (RMDs) …

Background Studies on long-term consequences of COVID-19, commonly referred to as post-
COVID condition, in patients with inflammatory rheumatic diseases are scarce and …

Before the global distribution of COVID-19 vaccines, we observed substantial concerns
among nonimmunocompromised people about the lack of longterm research or the …

Background Research on the disease severity of COVID-19 in patients with rheumatic
immune-mediated inflammatory diseases (IMIDs) has been inconclusive, and long-term …